Phosphodiesterase (PDE) Inhibitors
Research aimed for treatment of cancer had been the focus of many industries and academic groups since last two decades. Phosphodiesterases (PDE) are often targets for such studies involving pharmacological inhibition, due to their unique tissue distribution, structural properties, and functional properties. Phosphodiesterases mainly comprise of a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. PDEs are therefore important regulators of signal transduction mediated by these second messenger molecules. PDE inhibitors can prolong or enhance the effects of physiological processes mediated by cAMP or cGMP by inhibition of their degradation by PDE. Therefore PDE inhibitors are suggested to have great therapeutic value in the adjunctive therapy of Cancer. PDE inhibitors have also been used for the treatment of non-malignant conditions like asthma, pulmonary hypertension and erectile dysfunction etc. Additionally, they have been identified as new potential therapeutics in areas such as coronary heart disease, dementia, depression, and schizophrenia. BioVision's PDE inhibitors portfolio included many inhibitors which can be used for the above mentioned studies.
